Macroautophagy (hereon referred as Autophagy) is a cellular housekeeping mechanism that uses a double membrane to target and engulf cell products forthe formation of autophagosomes. These double membrane organelles then fuse to lysosomes where cell products aredegraded and recycled (Nakamura and Yoshimori, 2018). The loss of autophagy function in the motor cortex has been associated with progression of neurodegenerative symptoms in Parkinsons disease (Kaila and Lang 2015; Fahn et al. 2004). To better understand the role of Beclin 1 and autophagy in neurons, we studied locomotion in C. elegansmutants for
bec-1. Locomotion in both homozygous (
bec-1 -/-) and heterozygous
bec-1(
ok691) (
bec-1 +/-) mutants showed significant defects (Figure 1). Homozygous
bec-1(
ok691)mutants backwards locomotion rates ranged between 3-8 body bends/minute at ages 1-7 days of adulthood and heterozygous
bec-1(
ok691)mutants were 6-9 body bends/minute at comparable ages. These defects in locomotion suggest a role of autophagy controlling behaviors that are neuronal dependent.Previous research has shown that loss of motor function could be a result of neurodegeneration (Fahn et al., 2004; Kalia and Lang, 2015). Additionally, C. elegans studies demonstrated that mutations in
bec-1associate with degeneration of muscle cells and aging (Herndon et al., 2002). Together, our findings and previous reportsindicate that autophagy gene product, BEC-1, may play an important role in motor neuron physiology, survival, or both. Jia and colleagues have observed collections of visible protein aggregates in nematodes that elicit locomotion defects (Jia et al., 2007). This conclusion should be considered as preliminary as we have not verified by an alternative line of investigation (e.g., a second allele or transgene rescue) that the observed phenotypes are specific to
bec-1(
ok691).However, our study is also consistent with previous findings in Parkinsons disease patients where accumulation of protein aggregates was associated with loss of autophagy and accelerated onsets symptoms of decreased motor function (Ermine et al., 2018; Fahn et al., 2004).